Study of Continuous OSI-906 Dosing

Multicenter, open-label, phase 1, cohort dose escalation.

The study will open with the QD schedule, with initiation of the BID schedule occurring after
observation of clinically significant related toxicity ≥ grade 2 in the QD schedule.

Dosing will be initiated on Day 1 with daily dosing (either QD or BID) continuing for 21
days.

Once the recommended phase 2 dose has been determined for the BID schedule, 2 expansion
cohorts will be opened: 1) Biomarker Expansion Cohort in patients with locally advanced or
metastatic colorectal cancer and 2) Diabetic Expansion Cohort in patients with advanced solid
tumors who have active Type 2 diabetes mellitus not requiring insulin or insulinotropic
therapy.

Inclusion Criteria:

- Histologically or cytologically documented malignancy that is now advanced and/or
metastatic and refractory to established forms of therapy or for which no effective
therapy exists. Patients in the Biomarker Expansion Cohort must have histologically
documented colorectal cancer that is locally advanced or metastatic and refractory to
established forms of therapy. These patients must have archival tissue available and a
lesion accessible for biopsy

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2, life expectancy
≥ 12 weeks

- Prior chemotherapy is permitted provided that a minimum of 3 weeks has elapsed. Prior
tyrosine kinase inhibitor therapy is permitted. Patients must have recovered from any
treatment-related toxicities (with some exceptions) prior to registration

- Prior hormonal therapy is permitted provided it is discontinued prior to registration
(with the exception of prostate cancer patients who have been on hormone therapy for
at least 3 months)

- Prior radiation therapy is permitted provided that patients have recovered from the
toxic effects. A minimum of 21 days must have elapsed unless the radiotherapy was
palliative and nonmyelosuppressive

- Prior surgery is permitted provided that wound healing has occurred prior to
registration

- Fasting glucose ≤ 125 mg/dL (7 mmol/L) at baseline (all patients except those in the
Diabetic Expansion Cohort). Patients in the Diabetic Expansion Cohort must have a
fasting glucose of ≤ 150 mg/dL (8.3 mmol/L) at baseline. If patients in the Diabetic
Expansion Cohort are being treated with non-insulinotropic oral antihyperglycemic
therapy, doses must be stable for ≥ 4 weeks prior to registration

- Potassium, calcium, and magnesium must be within normal limits (WNL). Electrolyte
abnormalities will be permitted if they are not clinically significant and if
treatment for the abnormality is initiated prior to Day 1

- Neutrophil ≥ 1.5 x 10^9/L, Platelet (PLT) ≥ 100 x 10^9/L; bilirubin ≤ 1.5 x upper
limit of normal (ULN), AST and ALT ≤ 2.5 x ULN or ≤ 5 x UNL if patient has documented
liver metastases; creatinine ≤ 1.5 x ULN

- Accessible for repeat dosing and follow-up, including pharmacokinetic sampling

- Patients must practice effective contraceptive measures throughout the study

- Provide written informed consent

Exclusion Criteria:

- History of any kind of stroke

- History of any psychiatric condition that might impair the patient's ability to
provide informed consent or participate

- History of allergic reaction attributed to a similar compound as study drug.

- Any type of active seizure disorder

- Previously diagnosed brain metastases

- Concurrent anticancer therapy

- Active or uncontrolled infections of serious illnesses or medical conditions that
could interfere with participation

- Pregnant or breast-feeding females

- Documented history of diabetes mellitus (all patients except those in the Diabetic
Expansion Cohort). Patients in the Diabetic Expansion Cohort may not have Type 1
diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or
insulin therapy

- Use of drugs with a risk of causing QT interval prolongation within 14 days prior to
Day 1 and while on study

- Use of glucocorticoids within 14 days prior to Day 1 and while on study

- History of significant cardiac disease unless well controlled (includes 2nd/3rd degree
heart block, ischemic heart disease, QTc > 450 msec, poorly controlled hypertension,
or congestive heart failure of New York Heart Association (NYHA) Class II or worse)